PharmaShots Weekly Snapshot (Jun 01-05, 2020)
1. Novartis Reports Results of Enerzair Breezhaler (QVM149) in P-IIIb ARGON Study to Treat Uncontrolled Asthma Published: Jun 04, 2020 | Tags: Novartis, Reports,
[Read More...]
Fresenius Kabi
Insights+ Key Biosimilars Events of May 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be
[Read More...]
Fresenius Kabi Signs an Agreement with Medec to Commercialize IDACIO (adalimumab, biosimilar) in Germany
Shots: Fresenius Kabi and Medec collaborated to offer IDACIO as an additional therapy option for rheumatologists and dermatologists to treat rheumatic illnesses. From
[Read More...]
Fresenius Kabi Reports the US FDA’s Acceptance of BLA for its MSB11455 (biosimilar, pegfilgrastim)
Shots: The BLA submission is based on analytical, PK/ PD, safety and immunogenicity data from two clinical studies that demonstrated equivalent PK/ PD
[Read More...]
Vifor Pharma and Fresenius Kabi Collaborate to Establish Joint Venture in China
Shots: The companies partnered to form JV focusing on the marketing, market access, and medical affairs activities for the IV iron portfolio. Vifor
[Read More...]
PharmaShots Weekly Snapshot (February 03-07, 2020)
WHO to Accelerate Global Research and Innovation Against Corona Virus Published: Feb 06, 2020 | Tags: WHO, Accelerate, Global, Research, Innovation, Against, Corona Virus
[Read More...]
Fresenius Kabi Reports the Availability of Glucagon Emergency Medicine Kit to Treat Hypoglycemia in the US
Shots: The new Glucagon Emergency Kit allows clinicians flexibility and choice to treat patients experiencing severe hypoglycemia and is convenient & easy to
[Read More...]
PharmaShots Weekly Snapshot (January 20-24, 2020)
1. Epizyme’s Tazverik (tazemetostat) Receives the US FDA’s Accelerated Approval as the First Therapy for Epithelioid Sarcoma Published: Jan 23, 2020 | Tags: Epizyme,
[Read More...]
Fresenius Kabi Forms a Joint Venture in Collaboration with Bio-Techne and Wilson Wolf to Advance Cell and Gene Therapies
Shots: The JV leverages the expertise of three companies that includes Wilson Wolf’s G-Rex technology, BioTechne’s proteins, reagents, media, and gene-editing technologies and
[Read More...]
Top Biosimilar Companies with Approved and Pipeline Products in the US and EU
Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases.
[Read More...]